Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?
Open Access
- 28 October 2020
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 4S,p. 32-34
- https://doi.org/10.37489/2588-0519-2020-s4-32-34
Abstract
Hyaluronidase is currently not included into Russian or foreign guidelines on the treatment of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported by evidence of clinical effectiveness. Hyaluronidase can only be used for COVID-19 within clinical trials.Keywords
This publication has 7 references indexed in Scilit:
- COVID-19 infection: the perspectives on immune responsesCell Death & Differentiation, 2020
- Guidelines on the management of acute respiratory distress syndromeBMJ Open Respiratory Research, 2019
- Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesisMatrix Biology, 2018
- Therapeutic Intra-arterial Hyaluronidase Infusion for Ophthalmic Artery Occlusion Following Cosmetic Facial Filler (Hyaluronic Acid) InjectionNeuro-Ophthalmology, 2014
- The role of hyaluronic acid in SEB-induced acute lung inflammationClinical Immunology, 2013
- Lung hyaluronan decreases during group B streptococcal pneumonia in neonatal piglets.American Journal of Respiratory and Critical Care Medicine, 1996
- Accumulation of Hyaluronan (Hyaluronic Acid) in the Lung in Adult Respiratory Distress SyndromeAmerican Review of Respiratory Disease, 1989